Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MITF | O75030 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9657022 | 0.94 | MC4R (0.46) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL14452096 | 0.92 | LMNA (0.42) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL11526582 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL10609369 | 0.80 | CYP1A2 (0.47) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL1985996 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL5986347 | 0.79 | LMNA (0.56) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL13479950 | 0.77 | KLK7 (0.54) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL29110155 | 0.77 | SMN1; SMN2 (0.53) | ALDH1A1LMNASMN1; SMN2MITFATM | |
| SCHEMBL9756750 | 0.76 | ESR1 (0.41) | ALDH1A1LMNAMAPTHTTHPGD | |
| SCHEMBL11918239 | 0.76 | CYP2C19 (0.41) | ALDH1A1LMNASMN1; SMN2MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245008-B1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARM CORP (KR) | 2013-02-20 | — | — | EP | disclosed |
| US-8178697-B2 | Method for the preparation of atorvastatin and intermediates used therein | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-8178697-B2 | Method for the preparation of atorvastatin and intermediates used therein | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-8178697-B2 | Method for the preparation of atorvastatin and intermediates used therein | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2011-01-20 | — | — | US | disclosed |
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2011-01-20 | — | — | US | disclosed |
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2011-01-20 | — | — | US | disclosed |
| EP-2245008-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | Chong Kun Dang Pharmaceutical Corp. (KR) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009093776-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-07-30 | — | — | WO | disclosed |
| WO-2006110918-A1 | PYRROLE COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015407-A1 | METHOD FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES USED THEREIN | HMGCR, PCSK9, CETP | ALDH1A1 1340/4885LMNA 280/4885SMN1; SMN2 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.